EGFR and lung carcinoma: In addition to EGFR mutations, ctDNA testing was also used for monitoring response or resistance to ALK inhibitors therapy in patients with lung cancer via identification of appearance of ALK variations, including ALK point mutations and rearrangements (11, 56).